Telix Pharmaceuticals (TLX) Receivables - Other (2026)

Telix Pharmaceuticals (TLX) has reported Receivables - Other for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Other fell 24.37% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (down 24.37% YoY), while the FY2025 annual figure was $1.3 million, down 27.22% from the prior year.
• Receivables - Other retreated to $1.3 million in Q4 2025 per TLX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Receivables - Other topped out at $1.7 million in Q4 2024 and bottomed at $1.3 million in Q4 2025.
• Historically, Receivables - Other has averaged $1.5 million across 3 years, with a median of $1.5 million in 2023.
• Annual changes were most pronounced in 2024 — Receivables - Other climbed 10.53% — and 2025, when it declined 24.37%.
• Telix Pharmaceuticals' Receivables - Other stood at $1.5 million in 2023, then gained by 10.53% to $1.7 million in 2024, then dropped by 24.37% to $1.3 million in 2025.
• Business Quant data shows TLX's Receivables - Other at $1.3 million in Q4 2025, $1.7 million in Q4 2024, and $1.5 million in Q4 2023.